These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6821170)

  • 1. [Correlation of urinary 5-S-cysteinyldopa with repeated remission of melanoma induced by DTIC combination chemotherapy].
    Inoi T; Mojamdar M; Ichihashi M; Mishima Y
    Nihon Hifuka Gakkai Zasshi; 1982 Sep; 92(10):1065-9. PubMed ID: 6821170
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
    Agrup G; Hafström L; Jönsson PE; Rorsman H
    Lakartidningen; 1978 Dec; 75(49):4599-600. PubMed ID: 364213
    [No Abstract]   [Full Text] [Related]  

  • 3. [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].
    Ichihasi M; Mojamdar M; Mishima Y
    Nihon Hifuka Gakkai Zasshi; 1981 Sep; 91(10):1045-9. PubMed ID: 6798247
    [No Abstract]   [Full Text] [Related]  

  • 4. 5-S-cysteinyldopa in the urine of melanoma patients.
    Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
    Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of malignant melanoma with dacarbazin (DTIC-DOME) with special reference to urinary excretion of 5-S-cysteinyldopa.
    Jönsson PE; Agrup G; Arnbjörnsson E; Hafström L; Rorsman H
    Cancer; 1980 Jan; 45(2):245-8. PubMed ID: 6153150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
    Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
    Paul E; Graef V; Ruppel R
    Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients].
    Paul E; Graef V; Ruppel R; Hellwich M
    Z Hautkr; 1983 Feb; 58(4):262-5. PubMed ID: 6405551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic evaluation of human malignant melanoma by urinary 5-S-cysteinyldopa dynamics: chemotherapy and surgery].
    Inoi T; Mojamdar M; Ichihashi M; Mishima Y
    Nihon Hifuka Gakkai Zasshi; 1984 Jan; 94(1):39-43. PubMed ID: 6433083
    [No Abstract]   [Full Text] [Related]  

  • 10. [Melanoma metabolites (proceedings)].
    Rorsman H
    Lakartidningen; 1978 Dec; 75(49):4596-7. PubMed ID: 723347
    [No Abstract]   [Full Text] [Related]  

  • 11. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
    Stewart RM; Miller S; Gunder M
    Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative studies between excretion of 5-S-cysteinyldopa and indole melanogens in urine].
    Beyer C; Fiedler H; Wohlrab W; Wozniak KD
    Dermatol Monatsschr; 1986; 172(9):541-4. PubMed ID: 3098590
    [No Abstract]   [Full Text] [Related]  

  • 13. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
    Morishima T; Tatsumi F; Fukada E; Saito M; Fujita M; Nagashima N; Hanawa S
    Arch Dermatol Res; 1983; 275(2):76-9. PubMed ID: 6409012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis.
    Agrup G; Agrup P; Andersson T; Falck B; Hansson J-A ; Jacobsson S; Rorsman H; Rosengrem A-M ; Rosengren E
    Acta Derm Venereol; 1975; 55(5):337-41. PubMed ID: 52967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and quantitation of 5-S-cysteinyldopa in melanotic and amelanotic melanoma in comparison with nonpigment cell tumors and it's urinary excretion.
    Mojamdar M; Ichihashi M; Mishima Y
    J Dermatol; 1979 Dec; 6(6):379-82. PubMed ID: 120380
    [No Abstract]   [Full Text] [Related]  

  • 16. [Urinary 5-S-cysteinyldopa levels in patients with malignant melanoma. Preliminary results].
    Césarini JP; Meunier M
    Rev Prat; 1975 Nov; 25(51):4037-9. PubMed ID: 1209143
    [No Abstract]   [Full Text] [Related]  

  • 17. The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience.
    Nixon PF
    Aust N Z J Surg; 1978 Feb; 48(1):17-21. PubMed ID: 276342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High-performance liquid chromatographic determination of urinary 5-S, 2-S-, 6-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa (author's transl)].
    Morishima T; Saito M; Fujita M; Fukada E; Hanawa S
    Nihon Hifuka Gakkai Zasshi; 1982 Jan; 92(1):53-6. PubMed ID: 6804671
    [No Abstract]   [Full Text] [Related]  

  • 19. Urinary free and conjugated 5-S-cysteinyldopa in normal subjects and in patients with melanoma.
    Graef V; Paul E
    Br J Dermatol; 1982 Jan; 106(1):53-7. PubMed ID: 6800394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary excretion of melanocytic metabolites in fertile women.
    Carstam R; Hansson C; Rorsman H; Rosengren E; Sjöberg NO; Wirestrand LE
    Acta Derm Venereol; 1985; 65(6):543-5. PubMed ID: 2420122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.